INTRODUCTION
Since its original description by Pfeiffer and Koch in 1892, 1 endotoxin was thought to play an important role in the pathogenesis of Gram-negative bacterial septic shock. 2, 3 It was widely assumed that agents that could remove endotoxin from the blood of septic patients would be of considerable clinical value. The precise nature of the interaction between endotoxin and the vertebrate host has been the subject of extensive study over the past century. The molecular details of LPS interactions with the innate immune response and the genes triggered by this microbial mediator are now better understood, [4] [5] [6] [7] but the fundamental importance of this molecule in human septic shock has yet to be entirely clarified. [7] [8] [9] [10] The weight of evidence indicates that while endotoxin may be sufficient to induce septic shock in human subjects, it may not be necessary for the development of the lethal syndrome of sepsis in actual clinical practice. The inability to demonstrate clearly a survival benefit through the use of anti-endotoxin agents in patients with septic shock 11, 12 has cast further doubt on the pathophysiological significance of endotoxin in human septic shock. This brief review will summarize the problems associated with the linkage between endotoxemia and mortality in severe sepsis. Despite a myriad of clinical and microbiological variables that alter the effects of endotoxin in septic patients, current evidence indicates that high endotoxin levels are, in fact, associated with an adverse outcome in human septic shock.
Factors that modulate the clinical relevance of endotoxin levels in human sepsis
There are a number of mitigating factors that may potentiate or attenuate the pathophysiological impact of endotoxin in the systemic circulation of septic patients. Some of the most salient features of these modifying factors are given in Table 1 . Since minute quantities of endotoxin are sufficient to induce a systemic inflammatory response in humans, assays for the measurement of bacterial endotoxin must be very sensitive with the ability to detect picomolar quantities of LPS. This necessitates a very sensitive bioassay such as the Limulus amebocyte lysate assay. 12, 13 Immunoassays have been plagued by difficulties finding a high-affinity cross-reactive antibody that recognized multiple different serotypes of bacterial endotoxin. 12 
Proceedings
The clinical relevance of endotoxin in human sepsis: a critical analysis Correlations between circulating endotoxin levels from the blood of septic patients with clinical outcome measures have proven to be rather difficult. The clinical impact of endotoxin in septic patients depends upon the kinetics of LPS release, the concentration of LPS binding proteins, the cellular responsiveness to endotoxin, and numerous other immunogenetic, microbiological and physiological variables. Failure to account for these variables adequately has limited the clinical utility of endotoxin measurement. Several clinical studies have associated high levels of LPS with an excess risk of morbidity and mortality in sepsis that is largely independent of the nature of the micro-organism responsible for the septic episode.
Monoclonal antibodies to the limited numbers of core oligosaccharide structures in LPS, or antibodies to the highly conserved, but not identical, lipid A component of bacterial endotoxin from different species could serve as the much needed cross-reactive antibody function for the development of such an immunoassay. The search continues for an immunoassay system that can be adapted for clinical use as a rapid endotoxin detection method. 13 In addition to the numerous technical difficulties involved in measuring low levels of endotoxin in biological fluids, the kinetics of endotoxin release are complex and highly variable depending upon a number of host-dependent cellular and humoral factors. Variable levels of LPSbinding serum proteins within the circulation can markedly alter the host response to LPS. 10, [14] [15] [16] High levels of HDL and perhaps other lipoproteins functionally inhibit LPS signaling at the cellular level. The levels of LPS-binding protein such as LBP, soluble CD14 and plasma lipoproteins vary remarkably in different patients over the course of severe illness such as septic shock. 14, 15 These LPS-binding proteins can markedly alter the host response to measurable levels of endotoxin in the circulation.
DNA polymorphisms of LPS-binding receptor molecules such as CD14 17, 18 and TLR4 19 affect LPS responses, and the cellular activation induced by LPS also varies depending upon the level of cellular responsiveness to LPS 20-23 (i.e. endotoxin tolerance or re-programming). Initial clinical reports indicate that patients with a polymorphism within the promoter region of CD14 (C to T transition at base pair -159) 17 or in the coding region of TLR4 (aspartate to glycine at position 299) 19 significantly alter the host response to Gram-negative bacterial pathogens and potentially worsen the outcome in severe sepsis. In a report by Gibot et al., 17 patients who are homozygous at position -159 for the TT genotype in the CD14 gene locus were more likely to develop lethal septic shock than patients with CT or CC genotypes. The D299G polymorphism in the TLR4 gene locus is over represented in patients with Gram-negative sepsis when compared to a control population. 19 Future studies with functional genomic analysis of septic patients should be able to define better the relative risks associated with specific genotypes in the presence of systemic microbial infections. 17, 19 Moreover, the overall host capacity to respond to LPS is dependent upon such clinical factors as the age, gender, and physiological reserve of each patient. The situation is further complicated by such factors as nutritional status, concomitant illness, co-infection, antimicrobial therapy, and co-morbid illness. [24] [25] [26] [27] The presence of co-stimulatory molecules produced by microbial pathogens may synergize or tolerize the host response to bacterial endotoxin. Bacterial DNA, 28 lipopeptides, lipoteichoic acid, peptidoglycan, 29 bacterial flagellin, 30 and other microbial components are recognized by Toll-like receptors of the innate immune response and alter the response of cells to LPS stimulation. For all these reasons, the simple measurement of LPS in the plasma of septic patients gives at best an incomplete picture of the impact of LPS on the pathophysiology of sepsis in individual patients. The dominant role of endotoxin as a microbial mediator in sepsis While a multitude of clinical, physiological and microbial elements contribute to the outcome of patients with septic shock, LPS nonetheless plays an important and perhaps a dominant role in the pathogenesis of septic shock. Two recent experimental findings support the view that endotoxin is at least the most potent microbial mediator of systemic inflammation related to Gram-negative bacterial infection. The first line of evidence is derived from studies of mRNA transcript frequencies from antigen presenting cells (APCs) exposed to bacterial LPS or whole bacterial cells from Escherichia coli. Huang and colleagues 31 have demonstrated that an exceedingly complex series of gene transcription frequencies are altered upon exposure to bacterial endotoxin and/or whole bacterial cells in the form of E. coli. It is of considerable interest to note that of the 466 genes that were up-regulated in dendritic cells upon exposure to whole cell E. coli, almost 88% of the gene transcript profile was replicated upon exposure to purified LPS alone. This suggests that a single molecule found in the outer membrane of Gram-negative bacteria induces the vast majority of genes initially expressed upon exposure to an entire Gram-negative bacterium. This indicates that LPS is the dominant molecule of Gram-negative bacterial origin that is recognized by the APCs of the innate immune response.
Further evidence suggesting a pivotal role of bacterial endotoxin is found in a recent report with the lipid Adeficient strain of Neisseria meningitidis. 32 This organism has a mutation in one of its lipid A synthetic genes and is unable to synthesize any lipo-oligosaccharide in the outer leaflet of this Gram-negative bacterium. This organism remains viable yet expresses no endotoxin whatsoever within its cell wall. When this bacterium is compared to wild-type N. meningitidis, its ability to induce TNF generation is at least 100-fold less than wild-type N. meningitidis. The LPS null strain of meningococcus appears to activate primarily immune effector cells through a TLR2-mediated cell signaling. These studies verify the remarkable potency of LPS as a signaling molecule that initiates the systemic inflammatory response by the innate immune system.
Clinical correlation of endotoxin levels with outcome in septic patients
There have been numerous studies in which bacterial endotoxin has been measured in the circulation of patients with severe sepsis and septic shock. 2, 7, 24, 27 Despite all the aforementioned limitations of measurements of LPS in biological fluids, a summary of the results compiled from the most recent studies reveals reasonably consistent findings. Endotoxin measurements from blood samples from many clinical studies verify the prognostic significance of endotoxemia and adverse outcome. 7, 9, [33] [34] [35] Most patients with endotoxemia and septic shock had low levels of serum endotoxin (< 500 pg/ml). 27 Patients with high levels of endotoxin are more likely to be in shock and are generally more likely to succumb from sepsis than patients with low or absent endotoxin. 24, 27 Endotoxin detection from blood samples generally has greater prognostic significance in the presence of Gramnegative bacteremia and septic shock. 36 A detailed metaanalysis of endotoxin detection studies dating back over 30 years by Hurley 37 has statistically significant association with Gram-negative bacteremia, particularly when the bloodstream isolate is a member of the non-Enterobacteriaceae. The presence of high levels of circulating endotoxin in the absence of bacteremia is apparently independent of the causative micro-organism responsible for sepsis. This finding indicates that much of the measurable endotoxin presumably emanates from endogenous Gram-negative microflora found on mucosal surfaces. In summary, while it is reasonably well established that high levels of bacterial endotoxin in the circulation portend a poor prognosis in the presence of septic shock, it is still unclear if removal of endotoxin from the plasma of septic patients improves their overall likelihood of survival.
It has yet to be demonstrated that specific targeting of endotoxin with therapeutic agents will significantly reduce mortality in established human septic shock. 2, 5, 11 Until this is accomplished, the putative benefits of reduction of endotoxin in patients with severe sepsis or septic shock will remain an unproven hypothesis. Further development of endotoxin detection systems would be greatly facilitated by unequivocal clinical evidence that anti-endotoxin strategies significantly affect the outcome of critically ill patients. Hopefully, current and future clinical investigations with agents that directly and effectively inhibit endotoxin activity will finally answer the central question of the functional relevance of endotoxin in clinical septic shock.
